Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

Launched by JULES BORDET INSTITUTE · Sep 25, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Ga68-FAPI-46 PET/CT to help doctors better assess patients with peritoneal carcinomatosis, which is a type of cancer spread in the abdominal cavity. The goal is to see how accurately this imaging method can identify cancer in patients with colorectal and ovarian cancer who are preparing for surgery intended to remove the tumors.

To participate in this trial, individuals must have a confirmed diagnosis of colorectal or ovarian cancer and either known or suspected spread of the cancer to the peritoneum (the lining of the abdominal cavity). They should be scheduled for surgery aimed at removing these tumors and must be in good overall health. Participants will undergo the Ga68-FAPI-46 PET/CT scan as part of their preoperative assessment, which could help doctors plan the best treatment approach. The study is currently recruiting patients aged 65 to 74, and both men and women are welcome to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven colorectal and ovarian cancer.
• • Known or suspected peritoneal metastases from the tumour of origin.
• • Scheduled for peritoneal complete cytoreductive surgery with curative intent with or without neoadjuvant chemotherapy.
• • ECOG (Eastern Cooperative Oncology Group) Performance status ≤2.
• • Signed written informed consent obtained before any study-specific screening procedures.
• Exclusion Criteria:
• • Non-resectable extra-abdominal metastasis and/or \>3 hepatic metastases on standard work-up
• • Known chronic inflammatory conditions including the intestinal system (eg. inflammatory bowel disease, Crohn's disease)
• • Pregnant and lactating women
• • Previous or concurrent malignancy diagnosed within the last 3 years except adequately treated in situ carcinoma of the cervix uteri and basal or squamous cell skin cancer.
• • Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.